Daily Market Movers 10-09-09

FEATURED COMPANY

SAN WEST INCORPORATED (OTCBB: SNWT)

Detailed Quote: http://www.otcpicks.com/quotes/SNWT.php

Company Profile: http://www.otcpicks.com/san-west-inc.htm

San West designs, manufacturers, sells and repairs off-road buggies, and additionally provides aftermarket performance products and accessories for off-road buggies; products are sold via three divisions: at retail store locations; via the online store and; through its growing dealer network. Buggy repair services are sold and fulfilled at the Santee California retail location.

SNWT News:

October 9 - San West Inc. Provides Historical Index of Corporate Announcements, Comments on Recent Developments

San West, Inc. (OTCBB: SNWT), a Company that designs, manufacturers, sells and repairs off-road buggies, announced the availability of corporate press releases disseminated prior to its recent name and ticker change from Human Biosystems (OTCBB: HBSY).

It has come to the attention of San West management that interested parties attempting to conduct an online search for information on the company under its new ticker symbol "SNWT" have at times been unable to access past corporate announcements highlighting some of our most significant achievements to date.

Therefore, the company has deemed it helpful to provide a comprehensive list of San West Inc. press releases issued prior to 9/28/09 as well as a link to each announcement online at our news-wire service www.marketwire.com.

Frank Drechsler, CEO of San West Inc., states: "I'm pleased to announce that the public will now be able to access a historical index of San West Inc.'s media communications. Now, the public can more easily see (1) the milestones that our growing Company has achieved; and (2) the positive direction that we are moving."

Mr. Drechsler added: "In addition, I feel that it is prudent at this time to provide an update on our 8/20/09 announcement regarding the opening of a new Buggy World Location in Orange County. After extensive due diligence and much deliberation we have decided to terminate this agreement in favor of what we believe to be a more lucrative opportunity and key ingredient to become a premiere 'Off-Road Superstore'. So, it is an exciting time for everyone here at San West and it is our intent to announce this attractive relationship to the public in the near future."

FEATURED COMPANY

GREEN ENERGY LIVE INCORPORATED (OTCBB: GELV)
"Up 81.82% in morning trading"

Detailed Quote: www.otcpicks.com/quotes/GELV.php

Company Profile: http://www.otcpicks.com/green-energy-live.htm

GELV is a fully reporting, publicly-listed engineering and technology company focused on developing and commercializing renewable energy gasification systems that convert biomass wastes, currently being dumped in land-fills, into fuel and other valuable co-products. What is unique about GELV is that its technology can rapidly and economically be deployed to the waste site rather than vice versa. Thus, a customer's specific needs are addressed through a complete equipment package with the smallest ecological footprint.

GELV News:

October 7 - Green Energy Live Patent for Liquefaction Technology Accepted

Green Energy Live (OTCBB: GELV) announced that the United States Patent Office accepted the company's patent for liquefaction technology. The official patent number is US 7,559,537. Karen Clark, CEO of Green Energy, commented, "The acceptance of our patent is another positive development for our company and shareholders, as our competitive position in the market place is further strengthened."

"One of the major problems with existing systems used to create alternative bio-fuels are their large size, not to mention the tremendous cost of hauling the feedstock to the plant," said Ms. Clark. "By integrating multiple components of the process, our technology eliminates the need for the expensive, extensive and potentially explosive connecting pipelines and turbine pumps that are commonly used now. Furthermore, because we can scale down the liquefaction process, it may now be brought directly to the source of feedstock — the farm, thus further reducing the ecological footprint of the system."

FEATURED COMPANY

MUSCLE FLEX INCORPORATED (OTC: MFLI)

Detailed Quote: http://www.otcpicks.com/quotes/MFLI.php

Company Profile: http://www.otcpicks.com/muscle-flex-inc.htm

Muscle Flex Inc. brings new products to market using direct response TV infomercials specializing in the health, fitness, wellness and hygiene sectors. As well, Muscle Flex Inc. develops and creates general television content for network and cable television distribution. Muscle Flex's corporate strategy is to develop new and innovative products for sale and distribution via its proprietary direct response marketing system and the creation of television media and shows for general network and cable broadcast.

MFLI News:

October 8 - Muscle Flex Developing a Strong Product Portfolio in the 'Water' Category to Include Filtration, Bottled Water and Health Infused Water

Muscle Flex Inc. (OTC: MFLI) (www.MuscleFlexInc.com) announced that it is developing a strong portfolio of "Water" related products to market using its direct response, online ecommerce and traditional retail methods. Muscle Flex® regards "Water" as potentially the most important ingredient in maintaining a healthy lifestyle and it is estimated that as much as 75% of Americans do not drink enough good clean water. Water consumption is one of Danny Alex's, the CEO and Founder of Muscle Flex Inc., 30 fitness rules to living a better and healthier lifestyle. Muscle Flex is developing a several water related products and will be included as one of Muscle Flex's main product categories.

Muscle Flex is currently finalizing an at-home water filtration product it expects to retail from between $19.95 - $29.95 that it intends to market via a 2 minute short form commercial. Muscle Flex is developing a comprehensive list of "Water" related products from easy at-home and on-the-go filtration products to bottled water and water that is infused with additional nutrients and enhanced benefits.

The benefits of drinking ample amounts of water are numerous:

* Dehydration can slow down one's metabolism as much as 3%
* One glass of water can shut down midnight hunger angst.
* Lack of water is considered the primary reason for daytime fatigue.
* Research indicates that 8-10 glasses of water a day could significantly ease back and joint pain for up to 80% of sufferers.
* A mere 2% drop in body water can trigger fuzzy short-term memory, trouble with basic math, and difficulty focusing on the computer screen or on a printed page.
* Drinking ample amounts of water daily has been found to decreases the
risk a number of negative human conditions and diseases.

"Water products are a major focus for Muscle Flex Inc.," commented Danny Alex. "If people drank 1 or 2 glasses of water when they felt sluggish, tired or fatigued, within minutes they would feel revived and come alive. Water is something that everyone MUST drink and everyone understands the importance of it. Muscle Flex will be a one-stop provider of real-life 'Water' solutions for people ... solutions that are innovative and that can easily be applied to anyone's lifestyle. Becoming and staying healthy is all about simple one-step at a time lifestyle changes that take hold and stick as permanent lifestyle changes. As with the majority of Muscle Flex products, the Muscle Flex lifetime guarantee will apply to our water related products. It shows our commitment to quality as well as building the brand name, Muscle Flex, that people trust and hold in high regard. Unequivocal consumer trust in Muscle Flex and in all Muscle Flex brands is critically important as an over-all corporate mission."

FEATURED COMPANY

MAGNUM D'OR RESOURCES (OTCBB: MDOR)

Detailed Quote: http://www.otcpicks.com/quotes/MDOR.php

Company Profile: http://www.otcpicks.com/magnum-resources/magnum-resources.htm

Magnum d'Or Resources, Inc. focuses in operating in recycling and waste management sectors. It intends to develop facilities that produce rubber powders, thermoplastics, and thermoplastics elastomers. Magnum holds licensing rights to various patents that would allow rubber to be devulcanized, specialty blend EPDM powders, and EPDM compounds. The company was founded in 1999 and is based in Ft. Lauderdale, Florida.

MDOR News:

October 8 - Magnum's Multiple Stage Shredding System Arrives at the Hudson, Colorado Site as Magnum Prepares to Begin Recycling Operations

Magnum D'Or Resources, Inc. (OTCBB: MDOR) announces the arrival of one of its large turnkey complete shredding and chipping system for its Hudson, CO site. This system is self contained but will be used as a plug and start electric driven system. Operational start-up and testing is anticipated shortly with initial operations commencing upon State and County review in the coming days at the facility.

With this new system in place at the site, Magnum Recycling USA can prepare to commence initial operations. This will include acceptance and processing of scrap tires at the facility which will allow for immediate revenues and cash flow for the company from the scrap tire disposal fees. Magnum expects to receive OTR tires almost immediately and auto & truck tires within the next several weeks. Schedule fees range from 5 to 10 cents per pound for light tires and 10 to 15 cents per pound for large Industrial or OTR tires. Visit http://magnumresources.net/usa to view all the pricing.

Magnum Recycling USA will also soon begin to shred previously disposed tires at the site as time permits in order to prepare raw feed product for the rubber powder production lines Magnum Engineering International ('MEI') will be developing and installing.

Additionally, MEI has commenced design and engineering work with its affiliates to develop a State of the Art Rubber Recycling plant at the Hudson, Colorado facility. It will utilize a variety of high technology applications and solutions, which will result in a profitable business model that assures quality, excellence and continual improvement of environmental performance.

MEI is also working closely with Magnum/SRI during development of the Hudson plant in order to determine the optimum solution for planned production of powders and 'Next Generation' custom compounds at other sites and facilities.

President of Magnum, Joseph Glusic, stated, "We are extremely excited about the delivery of equipment at the Hudson site and look forward to the near future when all our operations will be in progress. It will be very interesting to watch this site take shape over the next several quarters to become one of the world's most advanced recycling operations. The opportunity to develop next generation technology and process applications seems limitless. Again, I would like to commend all those involved in supporting our transition, especially the State and County officials and staff members that have been extremely helpful during this period. These are exciting times indeed for Magnum as we begin to build upon our foundation and execute our business plan."

October 7 - Magnum Engineering International Launches New Corporate Website and Image to Better Inform Its Worldwide Presence

Magnum D'Or Resources, Inc. (OTCBB: MDOR), a next generation rubber recycling Solutions Company, wholly owned subsidiary, Magnum Engineering International, Inc. ('MEI') debuts its new corporate image.

Shareholders and prospective clients are invited to view the new site by visiting www.magnumei.com where they will find easy access to all of the Company's latest news and published information. "We hope that this new website will assist shareholders and interested parties to better understand our business and opportunities," stated a MEI company representative.

MEI's website will be updated regularly and will provide current, potential, and future clients and investors with all the necessary information in relation to current and future projects and solutions.

"I am pleased to announce this is just one more step taken to further enhance MDOR's Worldwide Corporate image," stated Magnum's CEO Joseph Glusic.

Furthermore, updates can be expected in the very near future which may include key agreements and trade show participations.

Magnum Engineering International To Provide Solutions for Magnum's USA and Canadian Operations

MEI to assume International Negotiations currently being conducted by MDOR

Magnum d'Or Resources, Inc. (OTCBB: MDOR), new division, "Magnum Engineering International, Inc. ('MEI')," announces strategic plans.

Magnum Engineering International ('MEI') is a wholly owned subsidiary of Magnum d'Or Resources ('MDOR'). Together with its affiliates MEI will develop turnkey plants and complete environmental solutions using a profitable business model that assures quality, excellence and continual improvement of environmental performance. MEI possesses the capacity to provide a complete range of 'one stop' services to its clients; no longer do clients have to deal with multiple sources for their needs, MEI can coordinate it all.

MDOR is awaiting delivery of the initial equipment necessary to commence work on the Colorado site. During this same period MEI will commence work on developing a full functioning recycling plant in Colorado using the latest available technology. MEI intends to develop this plant while working closely with Magnum/SRI to determine the optimum solution for the output.

MEI will also assume all responsibilities, including all inquires, discussion and International negotiations currently being conducted by MDOR in relation to third party recycling solutions.

MDOR CEO Joseph Glusic stated, "Since the establishment of Magog and the more recent release of results relating to Magnum/SRI, as well as, the acquisition of one of the largest tire Monofills in the world, we have gained significant recognition in the tire recycling industry. Due to the most current events alone we have been receiving a huge volume of inquiries from national and international companies regarding assistance for solutions to their tire recycling issues. We are currently in negotiation with several of those companies regarding various levels of services and support. Magnum Engineering International (MEI) has now been given the task and the responsibility of handling third party inquires and solutions in addition to assisting the Magnum group with all technical and engineering services."

FEATURED COMPANY

BIOMAGNETICS DIAGNOSTICS CORPORATION (OTC: BMGP)
"Up 5.26% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/BMGP.php

Company Profile: http://www.otcpicks.com/biomagnetics-diagnostics/biomagnetics-diagnostics.htm

Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company. The Company's revolutionary diagnostic systems, which are based on advanced magnetics, test for any viral or bacterial disease using any body fluid. The Company's technology allows laboratories to perform far more tests in the same amount of time it takes to do a single test. The HTS-MTP platform is designed to detect the actual virus and viral load in body fluids and not just simply screen for the presence of viral antibodies.

BMGP News:

October 8 - Biomagnetics Diagnostics Appoints Charles Gregoire de Rothschild Special Advisor to Board

Biomagnetics Diagnostics Corp. (OTC: BMGP), a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis HIV and hepatitis testing, announced the appointment of international financier Charles Gregoire de Rothschild to the role of special advisor to the Company's board of directors. Mr. de Rothschild will support Biomagnetics’ continuing global expansion efforts by leveraging his extensive domestic and international financial expertise.

“Western countries are finally waking up to the ongoing malaria crisis, which claims more than one million lives each year, commented Mr. de Rothschild. “While there have been some notable gains in malaria prevention over the past few years, the area of malaria testing and diagnostics has progressed very slowly. The world is in desperate need of low-cost, field deployable tools to diagnose malaria.”

For nearly 100 years, the direct microscopic visualization of the malaria parasite on blood smears has been the accepted method the diagnostics of malaria in most settings. This process must usually be performed in a laboratory setting by trained personnel. While field deployable, non-microscopic tests have been introduced, the efficacy of these tests is often called into question.

Mr. de Rothschild continued, “I and my investment firm, GDR Privee, wish to do our parts to advance this area of research by providing support to develop better diagnostic tools. We have reviewed the technology under development by Biomagnetics Diagnostics and believed it to be revolutionary holding the potential to cut the cost of testing by nearly two thirds. Additionally, because the technology is handheld, portable and easy to use, testing can be conducted by relatively untrained medical personnel. We believe the development of this technology could potentially save tens of thousands of lives each year and we wish to help speed its entry to market. I am proud to have become a major shareholder in Biomagnetics Diagnostics Corporation.”

According to the World Health Organization, some 3.2 billion people, or about half the world's population is at risk of malaria transmission in 107 countries and territories worldwide. While there are between 350 million and 500 million new cases of malaria each year, there are very few reliable and field deployable diagnostic tools available. Early detection substantially improves treatability and survivability. Field deployable integrated optical biosensor systems, such as those under development at Biomagnetics Diagnostics, hold the promise to significantly speed the diagnostic testing process and to meaningfully lower costs.

October 7 - Biomagnetics Diagnostics Subject of a New Research Report

Report Outlines a $0.75 to $1.10 Per Share Valuation

Biomagnetics Diagnostics Corp. (OTC: BMGP), a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, announced the Company is the subject of a new research report issued by Emerging Growth Research, LLP. The report outlines the Company’s growth prospects in the next generation medical diagnostics systems market with a particular emphasis on integrated optical biosensor systems that Biomagnetics plans to soon introduce into the malaria and bovine tuberculosis testing markets. A full copy of the report can be viewed at:

www.thesmallcapinvestor.com/tsci_details.php?id=54.

“We are very pleased to have this report available to current and prospective investors. We are planning to introduce some groundbreaking testing and diagnostic capabilities over the next few months and this report does an excellent job in explaining our strategies,” commented Clayton Hardman, CEO of Biomagnetics. “We also find it exciting that the report outlines a valuation of approximately $0.75 to $1.10 per share upon introduction of the advanced malaria and bovine tuberculosis sensors.”

According to the World Health Organization, some 3.2 billion people, or about half the world's population is at risk of malaria transmission in 107 countries and territories worldwide. While there are between 350 million and 500 million new cases of malaria each year, there are very few reliable and field deployable diagnostic tools available. In the case of malaria, early detection substantially improves treatability and survivability. TB (tuberculosis) is the second leading cause of death from infectious disease worldwide. Bovine TB is a growing problem through out the world with an estimated 1.3 billion cattle at risk. In the United States, where the cattle industry is valued at $60 billion annually, the use of existing diagnostic tests currently add $5.00 to $15.00 on average per head to the cattle industry's costs. Field deployable Integrated Optical Biosensor Systems (IBOS), such as those Biomagnetics Diagnostics is planning to soon introduce hold the promise of significantly speeding up the diagnostic testing process and meaningfully lowering costs and improving lives.

STOCKS TO WATCH

SCIENTIFIC LEARNING CORPORATION (NASDAQ: SCIL)
"Up 80.29% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/SCIL.php

Scientific Learning creates educational software that accelerates learning by improving the processing efficiency of the brain. Based on more than 30 years of neuroscience and cognitive research, the Fast ForWord® family of products provides struggling readers with computer-delivered exercises that build the cognitive skills required to read and learn effectively. Scientific Learning's Reading AssistantTM combines advanced speech recognition technology with scientifically-based courseware to help students strengthen fluency, vocabulary and comprehension to become proficient, life-long readers. The efficacy of the products has been established by more than 550 research studies and publications.

SCIL News:

October 9 - Scientific Learning Reports Preliminary Record Third Quarter Results and Board Member Resignation

Scientific Learning Corporation (Nasdaq: SCIL), a leading provider of technologies for accelerated learning, today announced preliminary financial results for the third quarter ended September 30, 2009. On a preliminary basis, total booked sales and revenues are expected to be record quarterly highs in the range of $25.5-$26.0 million and $19.0 to $20.0 million, respectively. The midpoint of these ranges would represent increases of 70% in booked sales and 54% in revenue versus the third quarter last year. Based on these preliminary booked sales and revenue figures, the company anticipates third quarter earnings per share in the $0.30-$0.34 range. During the third quarter, the company paid off the $2.5 million balance on its line of credit, and in addition, expects to end the quarter with cash and cash equivalents in the range of $16-$17 million. The company currently anticipates reporting its full third quarter results the week of October 26th.

Andy Myers, Chief Executive Officer stated, “Our strong preliminary third quarter results were driven by improvement in the overall funding environment and sales and productivity initiatives put in place over the past 18 months. On the funding side, the flow of federal stimulus funds to individual school districts and the spending requirements linked to these funds have put school districts in a better position to execute new purchases. On the sales and productivity side, process, organizational and incentive changes implemented over the past year-and-a-half have resulted in meaningful improvements in sales productivity and increased operating leverage. As a result, we are closing more business and improving margins. As previously disclosed, the quarter’s booked sales also benefited from a large $6.9 million deal that closed in early July. Looking ahead, we are moving into the seasonally slower fourth and first quarters in K-12, but our pipeline of potential new business remains healthy and we continue to be optimistic about our business.”

Separately, the company also announced today that board member David W. Smith has resigned from the company’s board of directors, effective October 8, 2009, in order to focus more of his time on his other professional and personal commitments.

Robert Bowen, Executive Chairman, stated, “The board and I would like to sincerely thank David for his many years of service and contributions to the company, and we wish him well in his future endeavors.”

The company believes that booked sales, a non-GAAP measure, is an important indicator of operating performance and has chosen to disclose these figures as part of its results. Booked sales should not be considered in isolation from revenue and is not intended to represent a substitute measure of performance calculated under GAAP.

NATURALNANO INCORPORATED (OTCBB: NNAN)
"Up 35.14% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/NNAN.php

NaturalNano, Inc. is a materials science company focused on developing and commercializing advanced nanocomposites. Based in Rochester, NY, the Company is focused on additive technologies and processes, including its proprietary Pleximer polymer additive, that add value to industrial polymers, plastics and composites, as well as consumer and industrial products. NaturalNano holds and licenses over 25 patents and applications, as well as proprietary know-how for extraction and separation processes, compositions, and derivatives of Halloysite and other nanotubes.

NNAN News:

October 8 - Cancer Cell's Capture Enhanced by NaturalNano's Halloysite Natural Tubes

NaturalNano, Inc. (OTCBB: NNAN) (Frankfurt: N3N) Acting CEO and President James Wemett announced today that the series of Cornell's feasibility studies using Halloysite Natural Tubes has been very successful. This has been initiated under the direction of Professor Michael King, Ph.D. of the Department of Biomedical Engineering at Cornell University in Ithaca, New York and in co-operation with CellTraffix Inc.

Dr. King states, "NaturalNano's proprietary Halloysite nanotubes have enhanced the cell adhesion of circulating cancer cells to reactive surfaces and are found to be non toxic to the cells. The Halloysite significantly decreased the rolling velocity and increased the number of cancer cells captured using these Natural Tubes."

Wemett said, "These results are very exciting to NaturalNano. We are continuing to work with Cornell and the Research Lab of Dr. King."

"The success of the combination of Halloysite nanotubes and Dr. King's technology significantly advances our progress in developing our device used commercially to isolate stem or certain cancer cells," said Thomas Fitzgerald, CEO of CellTraffix, which is commercializing the research done by Dr. King and his team.

ABOUT CELLTRAFFIX INC.

CellTraffix employs its unique understanding of the mechanics of cellular flow and cell trafficking in the blood stream to develop a range of proprietary medical devices. These are based on the CellSelect technology ranging from simple, low cost research tools for the separation and collection of cells in blood, to sophisticated in vivo and ex vivo therapeutic delivery systems and diagnostics to address a number of unmet medical needs relating to cancer, adult stem cells and immune cells.

HOLLIS-EDEN PHARMACEUTICALS (NASDAQ: HEPH)
"Up 5.08% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/HEPH.php

Hollis-Eden Pharmaceuticals, Inc. is developing a new series of small molecule compounds that are metabolites or synthetic analogs of endogenous hormones derived by the adrenal glands from the body’s most abundant circulating adrenal steroid. The Company’s clinical drug development candidates include TRIOLEX™ (HE3286), a next-generation compound currently in clinical trials for the treatment of type 2 diabetes, ulcerative colitis and rheumatoid arthritis, and APOPTONE™ (HE3235), a next-generation compound in a clinical trial for the treatment of late-stage prostate cancer.

HEPH News:

September 16 - Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price

Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), a leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, announced that it received a letter from The NASDAQ Stock Market on September 15, 2009.

The letter states that Hollis-Eden is not in compliance with Nasdaq Marketplace Rule 4450(a)(5) (the "Minimum Bid Price Rule") because its common stock had closed below $1.00 per share for 30 consecutive business days. The letter also states that in accordance with Nasdaq Marketplace Rules, Hollis-Eden has 180 days, or until March 15, 2010, to regain compliance with the Minimum Bid Price Rule. This letter has no immediate effect on the NASDAQ listing or trading of Hollis-Eden's common stock.

Hollis-Eden will regain compliance with the Minimum Bid Price Rule if the bid price of its common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days before March 15, 2010. However, if Hollis-Eden does not regain compliance with the Minimum Bid Price Rule by March 15, 2010, the Nasdaq staff will provide Hollis-Eden with a written notification that its common stock is subject to delisting.

Hollis-Eden will monitor the bid price for its common stock and consider available options.

XTEND MEDICAL CORPORATION (OTC: XMDC)
"Up 50.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/XMDC.php

XTend Medical is a company that specializes in the manufacturing and distribution of the latest in telemedicine and telehealth solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their continued efforts in identifying global companies with true product potential in the healthcare industry puts them in an advantageous position to capitalize on a global basis.

XMDC News:

October 6 - Letter to Shareholders of XTend Medical From the CEO Regarding the Upcoming Merger With BioHarp, Korea

XTend Medical Corp. (OTC: XMDC), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, released the following letter from the CEO, Mr. Paul D. Lisenby, regarding the upcoming merger with BioHarp, Korea and other corporate progress.

"To all XTend shareholders, I want to bring everyone up to date on the upcoming merger with BioHarp, Korea, and to share some insight into the future of the company. As you are aware from our most recent press release, we've decided to merge our company with BioHarp, Korea in order to have one of the most intriguing and cutting-edge medical devices to hit the healthcare industry in decades. The potential for this device to change the way patient diagnostics are currently being done is tremendous. The BioHarp is a non-invasive scanning device that can be used by a trained professional to scan the body to find cellular inflammation, utilizing nano bio-sensors. In layman's terms, whenever there is inflammation in the body on a cellular level, the potential for health issues can result. The BioHarp is a patent protected device that doesn't require any dyes or foreign fluid to be introduced into the body to attain a reading, or better yet, gives the patient results based on their individual body baseline. In short, this device can be used as an early diagnostic device by any country, healthcare company, managed care company, military, and in almost any other situation where an early diagnosis can assist in saving lives and lowering healthcare costs.

The work done by our management team with the principles at BioHarp, Korea, has taken us over two years to get to this point in our relationship wherein we feel comfortable merging with their organization and they feel the same way with us. Our hard work over the past three years in dealing with managed care companies, physician groups, and other healthcare organizations will prove to be most beneficial in securing future contracts for the BioHarp once the merger is complete. BioHarp, Korea has spent the last 14 years working on bringing the BioHarp unit to its current level of perfection and by combining our resources we gain solid management, premiere manufacturing, and the potential for a global company that will make BioHarp the most used medical device in early diagnosis.

There was a press release in February 2008, issued by Hathaway Corporation, announcing a joint venture with UNI Bio-Tech for the BioHarp device. As I was with the company at that time acting as the interim CEO, I knew the value of BioHarp. However, since the Board of Directors of Hathaway decided to change their business model to become FutureWorld Energy and focus their efforts on the renewable energy sector, the joint venture never took place and the deal was cancelled in April of 2008. My work with Hathaway has since stopped and for the last 18 months my sole responsibility has been to ensure XTend Medical brings value to our shareholders and puts itself in a position to capitalize on opportunities to grow the company. Through this merger, the company will become a global leader in the healthcare sector and it will be up to all of us here at XTend Medical and BioHarp, Korea to ensure that this happens.

Since the announcement of this merger, we have been working hard with Pink Sheets to become fully compliant with their reporting requirements. We should have this accomplished by week's end and hopefully have the Stop Sign removed from our company's profile. Our goal is to move up to a greater exchange due to the potential sales that we anticipate the BioHarp will be doing globally very soon. We are working with our accountant and legal teams to ensure that we have everything in order so the migration to a higher exchange can be accomplished at the proper time. Any changes we've recently made to the corporate structure are to effectuate this merger and any and all shares issued for this merger are subject to Rule 144 Restrictions. As we update Pink Sheets, the information will be there for all shareholders to review. We are in the process of updating our site and will share additional information about our progress in future press releases. In closing, I would like to thank all of our loyal shareholders for their dedication and for potential future shareholders; this company will be strong and have a very bright future for many years to come."

ZEVOTEK INC. (OTC: ZVTK)
"Up 41.18% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/ZVTK.php

Zevotek, Inc. plans to market and sell independently a range of distinct and independent lines of home care and household products. In May 2007, the company entered into a license agreement to sell an energy saving compact fluorescent light bulb named the Ionic Bulb. The company plans to market the Ionic Bulb through TV infomercials, catalogs, magazines and major U.S. retail and specialty stores.

ZVTK News:

October 7 - Zevotek Clears Path for New Financing

Zevotek, Inc. (OTC: ZVTK) (Frankfurt: T5V1), a designer, developer, and worldwide direct marketer and distributor of innovative personal and home care items, announced that it has terminated its factoring agreement with Star Funding, Inc. and severed the lender's security interest in Zevotek's Ionic Bulb sales program. Zevotek announced that the termination and release was achieved by mutual agreement and did not require payment by either party.

Commenting on the announcement, Zevotek's CEO, Adam Engel, said, "I look forward to announcing a new funding deal, which will have been made possible by terminating the Star Funding agreement. Zevotek is no longer subject to their control over our Ionic Bulb business. The factoring agreement Zevotek had in place was not designed to finance our business of selling Ionic Bulbs using our new TV ad. Zevotek's new financing will fit the mass market sales program we are rolling out."

Zevotek plans to sell Ionic Bulbs using a new 2-minute TV infomercial. The Ionic Bulb combines the performance features of ionic air cleaning technology with those of a 10,000 hour reduced energy use compact fluorescent light bulb (CFL). The new Ionic Bulb infomercial is expected to be ready to for TV and Internet audiences in November 2009. When Zevotek's Ionic Bulb infomercial is broadcast, viewers in homes across the U.S. can see the vivid demonstration of the bulb's ionizing action and immediately contact Zevotek to buy the Ionic Bulb and take advantage of its excellent value and many uses.

METABASIS THERAPEUTICS INCORPORATED (NASDAQ: MBRX)
"Up 47.17% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/MBRX.php

Metabasis Therapeutics is a biopharmaceutical company committed to the discovery, development and commercialization of novel drugs for metabolic diseases using its proprietary technology and its knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. The Company has established a broad pipeline of product candidates and advanced discovery programs targeting large markets with significant unmet needs. The Company’s product pipeline includes clinical-stage product candidates and advanced discovery programs for the treatment of metabolic diseases such as diabetes and hyperlipidemia, as well as product candidates and advanced discovery programs for the treatment of liver diseases such as hepatitis and primary liver cancer. All of the Company’s product candidates were developed internally using its proprietary technology and know-how.

MBRX News:

September 18 - Metabasis Therapeutics Receives Notice of Noncompliance with Nasdaq Listing Requirements

Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”), notifying the Company that based upon the closing bid price of its common stock for the last 30 consecutive business days, the Company did not maintain a minimum closing bid price of $1.00 per share or more that is required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, or until March 15, 2010, in which to regain compliance. If at anytime during this grace period the closing bid price of the Company’s common stock is $1.00 per share or more for a minimum of 10 consecutive business days, Nasdaq will provide the Company with written confirmation of regained compliance.

Metabasis is a biopharmaceutical company that has discovered novel drugs for metabolic diseases using its proprietary technology and its knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. The Company has established a broad pipeline of product candidates and advanced discovery programs targeting large markets with significant unmet needs. The Company’s product pipeline includes clinical-stage product candidates and advanced discovery programs for the treatment of metabolic diseases such as diabetes and hyperlipidemia, as well as product candidates and advanced discovery programs for the treatment of liver diseases such as hepatitis and primary liver cancer. All of the Company’s product candidates were developed internally.